This federal Project Grant award of $614,749 from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) supports research into the therapeutic value and mechanistic action of the PSPC1 protein in acute myeloid leukemia (AML).
The primary grantee, the University of Texas Health Science Center at San Antonio, will lead investigations to understand the role of PSPC1 in AML development and progression, with the goal of identifying potential new diagnostic, preventive, or therapeutic approaches. This 5-year grant, with a start date of June 1, 2024, will fund a range of activities, including creating and characterizing PSPC1 knockout mouse models, conducting genomic and proteomic analyses to delineate PSPC1's transcriptional targets and interacting proteins in AML, and evaluating the functional impact of PSPC1 loss or gain-of-function.
The grant also includes a sub-award to Columbia University's Health Sciences Division to support specific research activities within the project's Aim 1 and Aim 3 objectives.
Generated 4/1/25, 2:59 AM